Global Health Ltd. Share Price

Overview

Global Health Ltd. share price is currently ₹1,245.14, up by ₹51.03 (4.27%) from its previous closing price of ₹1,194.11. The share price has declined -15.71% over the past month and declined -7.65% over the past year. The stock's 52-week low and high are ₹946.00 and ₹1,531.64, respectively. Global Health Ltd. has a market capitalisation of ₹ 31,820.00 Cr. The share price was last updated on 27 Oct 2026, 03:30 PM IST.

Global Health Ltd.
Global Health Ltd.
MEDANTA
 ₹0.00
 ₹51.03
4.27%
Healthcare
 ₹0.00(%)1D

Updated: 27 Oct 2026, 03:30:02 pm IST

Market Data

Open Price

 ₹1,194.96

Prev. Close

 ₹1,194.11
 ₹1,189.27

Day Low

 ₹1,258.18

Day High

 ₹946.00

52 Week Low

 ₹1,531.64

52 Week High

HealthcareHospital & Healthcare Services
CategoryMid Cap

Fundamentals

Quick Bite

Price To Earnings Ratio

60.18

Sector PE

41.22

PB Ratio

8.48

Sector PB

5.35

EPS

20.69

Dividend Yield

0.05

Today's Volume

143.350 K

5 Day Avg. Volume

228.263 K

PEG Ratio

3.87

Market Cap.

₹ 31,820.00 Cr.

StockGro Trade views

Technical Analysis

Forecasts 🧭

Financials

Corporate Actions

ActionsEx-DateRecord-Date
DividendsFinal Dividend of 25% at ₹0.5/Share
14-Aug-202614-Aug-2026
DividendsFinal Dividend of 25% at ₹0.5/Share
22-Aug-202522-Aug-2025

Mutual Fund Ownership

Mutual Fund Holder
Aug 26
Shares held
Sep 26
Shares held
Kotak Mid Cap Fund - Regular Plan - Growth88.83 Lac
88.83 Lac
no change
Invesco India Midcap Fund - Regular Plan - Growth45.77 Lac
45.77 Lac
no change
UTI Flexi Cap Fund - Regular Plan - IDCW33.69 Lac
32.88 Lac
(2.41%)
Invesco India Smallcap Fund - Regular Plan - Growth21.94 Lac
21.94 Lac
no change
Invesco India Contra Fund - Regular Plan - Growth21.02 Lac
21.02 Lac
no change

About Global Health Ltd. 👋

Global Health Limited (Medanta) is an India-based multi-specialty tertiary care provider in the North and East regions of India. Medanta delivers advanced, end-to-end healthcare in Delhi, Gurugram, Indore, Ranchi, Patna, and Lucknow through its network of approximately five hospitals. Medanta provides healthcare services in over 30 medical specialties and engages over 1,800 doctors. Its specialty treatments are in cardiac care, cancer care, neurosciences, orthopedics, renal care, liver transplants, oncology, bone marrow transplant, obstetrics and gynecology, chest surgery, lung transplant, pediatric care, ENT, head and neck surgery, and others. Its facilities and services include medicine delivery, lab tests & diagnostics, homecare services, health checkups, elder care, air ambulance, among others. Its subsidiaries include Global Health Patliputra Private Limited, Medanta Holdings Private Limited, and GHL Pharma & Diagnostic Private Limited.

Expert Opinions

Insights from SEBI-registered analysts · updated live

Explore all →
Jeet B Bhayani (SEBI RA)

Jeet B Bhayani (SEBI RA)

26 Oct • 3:36 PM · SEBI-Registered Analyst

India Makhana Production & Export Outlook

India exported over 7,000 metric tonnes of makhana and value-added makhana products to more than 20 international markets in FY26, including the United States, the Middle East, and Africa, according to the Ministry of Commerce. As the world’s largest producer, India’s cultivation is primarily concentrated in Bihar, West Bengal, and Assam, with Bihar alone accounting for nearly 85% of total domestic production. The GI-tagged Mithila Makhana is gaining widespread international recognition for its rich nutritional profile and culinary versatility. Supported by rising global health consciousness, innovative startups creating ready-to-eat consumer products, and active participation from Farmer-Producer Organisations (FPOs), the sector is rapidly transitioning from a regional specialty into a global superfood category. To formalize trade and accelerate export growth, the Government of India implemented a dedicated Harmonised System (HS) code for makhana in July 2025, enabling precise tracking in international trade databases. This was followed by the launch of the National Makhana Board in Bihar on September 15, 2025, alongside the approval of a ₹476.03 crore ($53.87 million) Central Sector Scheme running through 2030–31, featuring targeted allocations of ₹30 crore ($3.39 million) for FY26 and ₹90 crore ($9.47 million) for FY27. Designed to modernize harvesting and post-harvest infrastructure, the scheme focuses on high-quality seed distribution, R&D, branding, export promotion, and quality assurance—enhancing Bihar’s agricultural incomes while expanding the global footprint of GI-tagged Mithila Makhana.

DABUR

See More
Ashish Kumar

Ashish Kumar

3 Oct • 4:01 PM · SEBI-Registered Analyst

Supreme Court Scrutiny on Medicine Mark-ups

Hospital stocks remain in the spotlight after the Supreme Court raised sharp concerns over steep mark-ups on medicines sold to patients at private hospitals. A bench flagged a cancer drug supplied to retailers at around ₹2,700 but carrying an MRP of ₹27,000 — nearly a tenfold difference — and questioned why the existing 16% trade margin cap on scheduled drugs has not been extended to non-scheduled medicines that dominate the market. The court also directed the Centre to examine practices compelling patients to buy from in-house or designated hospital pharmacies. The matter is listed for further hearing on October 12. The remarks triggered a sharp sell-off, with the BSE Hospitals Index falling about 5% and chains such as

MAXHEALTH
Healthcare, KIMS and others declining 5-6%. Brokerages have assessed the potential earnings hit. Goldman Sachs estimates a 2-7% EBITDA impact in scenarios with no mitigation, though it notes that modest pricing adjustments or greater use of package billing could cushion the effect. Emkay remains constructive on the sector, assigning Buy ratings to KIMS (target ₹850) and Park Medi World, and Add ratings to Max Healthcare (₹1,150), Global Health/Medanta (₹1,500) and Rainbow Children’s Medicare (₹1,550).

See More
DEEPAK PAL

DEEPAK PAL

30 Sep • 2:19 PM · SEBI-Registered Analyst

Hospital Stocks CRASH! Supreme Court Questions ON!

HOSPITAL RISK-->“Sarkari Hospital Mein Jaan Ka Risk… Private Hospital Mein Jameen-Jaydaad Ka Risk!” erns over steep mark-ups on medicines sold through private hospitals. Stocks including

APOLLOHOSP
, Max Healthcare, Fortis Healthcare, Yatharth Hospital, Medanta and Aster DM came under pressure, with several names falling sharply during the session. --->What Did the Supreme Court Question? The Supreme Court was hearing petitions related to medicine pricing, generic prescriptions and medical-device pricing under the Drugs (Prices Control) Order, 2013. During the hearing, the bench highlighted a striking example: A cancer medicine supplied to retailers for around ₹2,700 was cited as carrying an MRP of around ₹27,000. The Court questioned how such a large gap could exist and also raised concerns about hospitals requiring patients to purchase medicines through their own or designated pharmacies. ---->Why Are Hospital Stocks Falling? The market is worried about one simple issue: Medicine mark-ups can be an important part of hospital economics. If hospitals are eventually required to operate with significantly lower medicine margins, it could potentially affect: • Pharmacy-related revenue • EBITDA margins • Profitability • Revenue per patient ---->The 16% Rule — Don't Misunderstand It This is where the headlines can become misleading. The Supreme Court questioned whether a uniform 16% margin could be applied more broadly. But: The Court has NOT ordered a universal 16% cap on all medicines. The existing 16% retailer-margin concept is already used in parts of India's drug-price-control framework for scheduled formulations. ---->Bottom Line Hospital stocks are falling because the Supreme Court has put hospital medicine mark-ups and captive pharmacy practices under the regulatory spotlight. The market is currently pricing in the risk of tighter regulation, not a confirmed 16% margin cap.

See More
Ujvin Nevatia

Ujvin Nevatia

29 Sep • 7:27 PM · SEBI-Registered Analyst

Medanta acquires ₹166 crore land in Ghaziabad

Research Analyst: UJVIN NEVATIA (PROPRIETOR: NEVAT INVESTMENTS) | SEBI Registration No.: INH100009628 Global Health Limited (

MEDANTA
), which operates Medanta hospitals, has acquired land in Ghaziabad for ₹165.82 crore to develop a multispecialty hospital with more than 350 beds. What happened? The company acquired a 10,560.36 sq. metre freehold land parcel in Siddharth Vihar through an online auction conducted by the Uttar Pradesh Housing & Development Board. The proposed hospital remains subject to approval of the detailed project plan and other regulatory clearances. Why does it matter? The acquisition expands Medanta's presence in Delhi-NCR, where it already operates hospitals in Gurugram and Noida. A new hospital could increase its patient reach and strengthen its regional network. However, land acquisition is only one component of the total project investment. My view Hospital expansion requires substantial upfront capital, while revenue builds gradually as patient occupancy increases. The important question is whether Medanta can use its existing brand and regional network to attract patients quickly enough to justify the investment. Construction costs, medical staffing and the time taken to reach optimal occupancy will determine the project's returns. What I am watching next I would track project approval, total investment, construction timelines and the expected commissioning date. Once operational, occupancy and average revenue per occupied bed will be important indicators. No Recommendations Source: Business Standard / Global Health exchange disclosure Disclosure: I, my entity, associates or relatives do not have any holding, position or other material interest in Global Health Limited.

See More
AALGO BREATHS I SEBI RA

AALGO BREATHS I SEBI RA

5 Sep • 2:42 PM · SEBI-Registered Analyst

GLOBAL HEALTH LTD – TECHNICAL ANALYSIS With Discussion

MEDANTA
Global Health Ltd is currently showing an interesting technical setup on the daily chart. The stock has witnessed a strong upward movement from lower levels and is now consolidating around the ₹1,470 zone. The overall price structure remains positive, but the recent candles indicate some volatility and profit booking near the higher levels. Traders should closely monitor the immediate support and resistance zones for the next directional move. The chart suggests that the ₹1,420–₹1,380 zone may act as an important support area. As long as the stock manages to sustain above this zone, the broader bullish structure may remain intact. On the upside, ₹1,500–₹1,540 appears to be an important resistance zone. A sustained breakout above this level could strengthen bullish momentum and may open the door for further upside. The moving averages and price structure indicate that the stock is currently in a consolidation phase after a strong rally. Volume and price action should be monitored closely for confirmation of the next trend. A breakout with strong volume may attract fresh buying interest, while a breakdown below the key support zone could increase selling pressure. Key Levels to Watch: 📈 Resistance: ₹1,500 | ₹1,540 | ₹1,585 📉 Support: ₹1,420 | ₹1,380 | ₹1,339 ⚠️ Disclaimer: This technical analysis is for educational and informational purposes only and should not be considered as investment advice. Please use proper risk management and consult a qualified financial advisor before making any trading or investment decision.

See More
AALGO BREATHS I SEBI RA

AALGO BREATHS I SEBI RA

26 Aug • 8:22 PM · SEBI-Registered Analyst

Global Health Ltd. – Bullish Setup Discussion

MEDANTA
The stock is currently consolidating near a key support zone, with fresh buying interest emerging after a strong bullish candle. Price action indicates that the support area around ₹1402–₹1438 is holding well, while short-term bullish momentum is gradually improving. The broader rising channel structure remains intact, keeping the overall technical setup positive as long as the important support levels are defended. 🔎 Technical View: • Strong support holding around ₹1402–₹1438 • Fresh buying interest visible near support • Bullish momentum showing signs of improvement • Rising channel structure remains intact • ₹1473 is the key breakout level to watch • Sustained price action above resistance may strengthen the bullish setup 🔑 Key Levels: 🟢 Support: ₹1438 / ₹1402 🟢 Major Support: ₹1367–₹1345 🔴 Resistance: ₹1473 / ₹1509 🚀 Potential Upside Levels: 🎯 ₹1473 🎯 ₹1509 🎯 ₹1545 🎯 ₹1580+ 📈 Trading View: A sustained move above ₹1473 could trigger fresh bullish momentum and potentially open the way towards ₹1509, ₹1545 and ₹1580+ levels. On the downside, ₹1402 remains an important risk level. A decisive breakdown below ₹1402 could weaken the current setup and increase the possibility of a move towards ₹1367–₹1345. Traders should closely monitor price action, volume and overall market conditions around these key levels, as volatility can impact the movement significantly. ⚠️ For educational purposes only. Not a buy/sell recommendation. Please conduct your own research and consult a SEBI-registered investment professional before making any investment decision. — AALGO BREATHS 📊

See More

News & Events

Frequently Asked Questions

What is the share price of Global Health Ltd.?

What is the market cap of Global Health Ltd.?

Should I buy Global Health Ltd. stock now?

What is the 52 week high and low of Global Health Ltd.?

Is the Global Health Ltd. stock good to buy?

Is Global Health Ltd. a good buy for the long term?

Is Global Health Ltd. overvalued or undervalued?

What is the PE and PB ratio of Global Health Ltd.?

Start Now